Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     
Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     


Temps Différé Japan Exchange  -  08:00 22/09/2022
1904.50 JPY   -1.86%
12/09Seagen, Merck, Astellas publient les données d'un essai de Padcev et Keytruda pour le traitement du cancer de la vessie
12/09Astellas, Seagen et Merck annoncent les résultats d'une étude clinique portant sur PADCEV(R) (Enfortumab Vedotin-Ejfv) avec KEYTRUDA((R) (Pembrolizumab) et PADCEV en monothérapie dans le cancer urothélial avancé de première intention
05/09Astellas Pharma Inc. Annonce les premiers résultats de l'étude de phase 3 sur l'innocuité à long terme du fezolinetant en Chine continentale
SynthèseToute l'actualitéAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur ASTELLAS PHARMA INC.
20/09Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
12/09Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
12/09Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
05/09Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
19/08Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
18/08ADRs End Lower, Geely Automobile Trades Actively
18/08U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
10/08Verizon Business selected to transform Astellas Pharma's global network infrastructure
10/08Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
09/08Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
02/08Astellas Pharma Shares Sink 3% as Weak Yen Drags Fiscal Q1 Attributable Profit Down
02/08Astellas Pharma Inc. Announces Executive Changes
01/08TRANSCRIPT : Astellas Pharma Inc., Q1 2023 Earnings Call, Aug 01, 2022
01/08ASTELLAS PHARMA : Financial Results (Q1/FY2022)
01/08ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2022)
01/08ASTELLAS PHARMA : Supplementary Documents (Q1/FY2022)
27/07Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
27/07Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
27/07Japan's Nikkei ends higher helped by chip stocks gains
27/07Japan's Nikkei little changed ahead of Fed meeting outcome
26/07SECTOR UPDATE : Health Care Stocks Steady Premarket Tuesday
26/07Seagen, Astellas Report Positive Results for Trials on Padcev with Keytruda as Treatmen..
26/07Astellas-Seagen's Bladder Cancer Therapy Shrinks Tumor in Phase 1b/2 Trial
26/07ASTELLAS PHARMA : and Seagen Announce Positive Topline Results For PADCEV with KEYTRUDA as..
26/07Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-e..
22/07Astellas Pharma Inc. Unveils Plans to Open New Biotech Campus in South San Francisco
21/07Dolphin Unit Closes $8 Million Purchase of High Reserve F&B in Cash-Stock Deal; Dolphin..
05/07Mogrify and Astellas Announces Collaboration to Conduct Research on in Vivo Regenerativ..
28/06Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma
28/06Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Nove..
28/06Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
27/06Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late..
27/06Astellas Pharma Inc. Announces FDA Update on Fortis Clinical Trial of AT845 in Adults w..
24/06WE PUBLISHED A STORY : “Astellas' Path to Sustainability Vol.1: A New Materiality Ma..
24/06ASTELLAS' PATH TO SUSTAINABILITY VOL : A New Materiality Matrix as a Compass to Direct our..
24/06Astellas Submits Fezolinetant New Drug Application to U.S. FDA
08/06Astellas Pharma Inc. Celebrates Opening of Large-Scale Gene Therapy Manufacturing Facil..
02/06Nikkei 225 Down 0.2% on Wall Street Cues, Central Bank Outlooks
02/06Japan's Nikkei edges back from 6-week high as Astellas, Sony drag
02/06Japan's Nikkei retreats from 6-week high as Astellas, Sony drag
26/05ASTELLAS PHARMA : Posted Notice of Convocation of the 17th Term Annual Shareholders Meetin..
26/05ASTELLAS PHARMA : Notice of Convocation of the 17th Term Annual Shareholders Meetingᦀ..
24/05Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson
23/05Astellas Pharma to Appeal US Court Decision on Patent Infringement Lawsuit
20/05ASTELLAS PHARMA : Confirms Unfavorable District Court Decision in LEXISCAN® 0.4mg/mL U.S. ..
12/05Astellas Pharma Inc. Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annu..
09/05Twist Bioscience Signs Research Collaboration, Exclusive Option License Deal With Astel..
09/05Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Aste..
05/05Astellas Pharma Inc. to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Tria..
27/04MÄRKTE ASIEN/Tokio und Seoul schwach - Erholungsrally in Schanghai
27/04TRANSCRIPT : Astellas Pharma Inc., 2022 Earnings Call, Apr 27, 2022
27/04ASTELLAS PHARMA : Changes of Representative Director and Directors
27/04ASTELLAS PHARMA : Financial Results (FY2021)
27/04ASTELLAS PHARMA : Supplementary Documents (FY2021)
27/04ASTELLAS PHARMA : Presentation Material for Information Meeting (FY2021)
26/04Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio..
25/04MÄRKTE ASIEN/Sehr schwach - Kursdebakel in Schanghai
25/04The University of Tokyo and Astellas Pharma Inc. Enter Second Phase of Strategic Partne..
25/04Astellas Pharma to Record $389 Million Impairment Loss on Products under Development
22/04ASTELLAS PHARMA : Notice Regarding Impairment Loss for Products under Development
22/04Astellas Pharma Inc. Provides Impairment Guidance for the Fourth Quarter Ended March 31..
14/04ASTELLAS PHARMA : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv..
13/04Seagen-Astellas Pharma Treatment for Urothelial Cancer Gets European Commission Nod
13/04Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™..
13/04European Commission Approves Drug for Urothelial Cancer
11/04Nikkei 225 Off 0.6% on Russia Outlook, Inflation Concerns
07/04Nikkei 225 Slides 1.97%, Extends Losses on Federal Reserve Outlook; IMF Cuts Japan GDP ..
07/04Japan's Nikkei sinks most in a month on Fed, China worries
07/04Japan's Nikkei hits 3-week low on Fed, China worries
05/04Singlera Genomics Announces Research Collaboration with Astellas Pharma Pursuing Methyl..
05/04WE PUBLISHED A NEW SUSTAINABILITY SE : “Developing a sustainable society by leveragi..
04/04Japan's Nikkei falls as chip shares track U.S. peers lower
01/04Australian Shares Post Small Loss Amid Decline in Business Confidence
01/04ASTELLAS PHARMA : We published a Drug Research page.
31/03Global Health Innovative Technology Fund Announces Collaboration with Astellas Pharma I..
15/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,933KB)
15/03Astellas Pharma Inc. Announces Topline 12-Week Results from Phase 3 Study of Fezolineta..
14/03WE PUBLISHED A STORY : “Reinvigorating the immune system to find new ways to cure ca..
14/03ASTELLAS PHARMA : Reinvigorating the immune system to find new ways to cure cancer
11/03Astellas Pharma Completes $428 Million Share Buyback
10/03Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Smal..
10/03ASTELLAS PHARMA : Meeting Script(8,030KB)
10/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancellation of T..
10/03Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on February 2, 2..
09/03ASTELLAS PHARMA : Update on ukraine
09/03TRANSCRIPT : Astellas Pharma Inc. - Special Call
09/03ASTELLAS PHARMA : Presentation Material for R&D Meeting
09/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,929KB)
09/03ASTELLAS PHARMA : Updated “R&D meeting” Section
09/03Astellas Pharma Inc.'s Equity Buyback announced on February 2, 2022, has expired with 2..
07/03Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant ..
07/03ASTELLAS PHARMA : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolin..
02/03Astellas Pharma Repurchases Shares for $255 Million
02/03WE PUBLISHED A STORY : “Astellas' VALUE powered by people—New Challenge of HR...
02/03ASTELLAS PHARMA : ' VALUE powered by people — New Challenge of HR
01/03ASTELLAS PHARMA : Meeting Script(4,467KB)
01/03ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
01/03Japanese shares rise on bargain-hunting, hopes for Russia-Ukraine talks
01/03ASTELLAS PHARMA : and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortuma..
01/03ASTELLAS PHARMA : Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent..
Prochain événement sur ASTELLAS PHARMA INC.